Just read the paper. The 33% headline is a lie. The lie is simple: they don't tell you in the headline that flu patients did poorly too, so the 33% is really about 10%. (blue is flu)
Just read the paper. The 33% headline is a lie. The lie is simple: they don't tell you in the headline that flu patients did poorly too, so the 33% is really about 10%. (blue is flu)
“Most diagnostic categories were more common in patients who had COVID-19 than in those who had influenza (HR 1·44, 95% CI 1·40–1·47 for any diagnosis; 1·78, 1·68–1·89 for any first diagnosis) and those who had other respiratory tract infections (1·16, 1·14–1·17 for any diagnosis; 1·32, 1·27–1·36 for any first diagnosis). Hazard rates were also higher in patients who were admitted to ITU than in those who were not (1·58, 1·50–1·67 for any diagnosis; 2·87, 2·45–3·35 for any first diagnosis). HRs were significantly greater than 1 for all diagnoses for patients who had COVID-19 compared with those who had influenza, except for parkinsonism and Guillain-Barré syndrome, and significantly greater than 1 for all diagnoses compared with patients who had respiratory tract infections (table 3).”
“The severity of COVID-19 had a clear effect on subsequent neurological diagnoses (Table 4, Table 5, figure 2). Overall, COVID-19 was associated with increased risk of neurological and psychiatric outcomes, but the incidences and HRs of these were greater in patients who had required hospitalisation, and markedly so in those who had required ITU admission or had developed encephalopathy, even after extensive propensity score matching for other factors (eg, age or previous cerebrovascular disease). Potential mechanisms for this association include viral invasion of the CNS,10, 11 hypercoagulable states,22 and neural effects of the immune response.9 However, the incidence and relative risk of neurological and psychiatric diagnoses were also increased even in patients with COVID-19 who did not require hospitalisation.
Some specific neurological diagnoses merit individual mention. Consistent with several other reports,23, 24 the risk of cerebrovascular events (ischaemic stroke and intracranial haemorrhage) was elevated after COVID-19, with the incidence of ischaemic stroke rising to almost one in ten (or three in 100 for a first stroke) in patients with encephalopathy. A similarly increased risk of stroke in patients who had COVID-19 compared with those who had influenza has been reported.25 Our previous study reported preliminary evidence for an association between COVID-19 and dementia.14 The data in this study support this association. Although the estimated incidence was modest in the whole COVID-19 cohort (table 2), 2·66% of patients older than 65 years (appendix p 28) and 4·72% who had encephalopathy (table 2), received a first diagnosis of dementia within 6 months of having COVID-19. The associations between COVID-19 and cerebrovascular and neurodegenerative diagnoses are concerning, and information about the severity and subsequent course of these diseases is required.”
“The findings regarding anxiety and mood disorders were broadly consistent with 3-month outcome data from a study done in a smaller number of cases than our cohort, using the same network,14 and showed that the HR remained elevated, although decreasing, at the 6-month period. Unlike the earlier study, and in line with previous suggestions,28 we also observed a significantly increased risk of psychotic disorders, probably reflecting the larger sample size and longer duration of follow-up reported here. Substance use disorders and insomnia were also more common in COVID-19 survivors than in those who had influenza or other respiratory tract infections (except for the incidence of a first diagnosis of substance use disorder after COVID-19 compared with other respiratory tract infections).”
“In summary, the present data show that COVID-19 is followed by significant rates of neurological and psychiatric diagnoses over the subsequent 6 months. Services need to be configured, and resourced, to deal with this anticipated need.”
6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records
The Lancet
Psychiatry
Maxime Taquet, PhD
Prof John R Geddes, MD
Prof Masud Husain, FRCP
Sierra Luciano, BA
Prof Paul J Harrison, FRCPsych
Open AccessPublished:April 06, 2021DOI:https://doi.org/10.1016/S2215-0366(21)00084-5
https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(21)00084-5/fulltext#tbl2
Link to the top of the report instead of a table.
https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(21)00084-5/fulltext